Offer - Urjas Oil for just ₹ 1 X
Olsavas is a prescription drug, available for use as Tablet. It is typically used for the treatment of High BP. Olsavas also has some secondary and off-label uses. These are listed below.
Medical history of the patient along with age and gender determines the dosage of Olsavas. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. This information has been provided in detail in the dosage section.
Olsavas also has some side effects, the most common being Upper respiratory tract infection. While these are the most often observed Olsavas side effects, there are can be others also. These have been listed below. These side effects of Olsavas are usually temporary and subside with the completion of treatment. Consult your doctor if these side effects become worse or stay for a longer duration.
It is also important to note that Olsavas has a Severe effect for pregnant women and Mild effect on lactating mothers. Warnings related to Olsavas's effects on the liver, heart and kidney, if any, have been listed below.
Olsavas can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Olsavas in conditions like Bradycardia (Slow Heart Rate), Low Blood Pressure (Hypotension). Other contraindications of Olsavas have been discussed in the sections ahead.
Drug interactions for Olsavas have been reported in the medical literature. A complete list of these interactions is given below.
Along with the above-mentioned precautions, remember that taking Olsavas is considered not safe while driving, and is not addictive.
Olsavas is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Is the use of Olsavas safe for pregnant women?
Olsavas should not be taken during pregnancy, or should only be taken on the advice of a doctor as it may have severe side effects.
Is the use of Olsavas safe during breastfeeding?
Side effects of Olsavas for breastfeeding are little to none, so you can take it without doctor's advice.
What is the effect of Olsavas on the Kidneys?
Olsavas may have mild side effects on the kidneys.
What is the effect of Olsavas on the Liver?
Olsavas is rarely harmful for the liver.
What is the effect of Olsavas on the Heart?
Olsavas has very mild side effects on the heart.
Olsavas should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Olsavas unless your doctor advises you to do so -
Is this Olsavas habit forming or addictive?
Olsavas is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
No, you should not drive or operate heavy machinery after taking Olsavas as you may feel sleepy.
Is it safe?
Olsavas is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
No, Olsavas cannot treat any kind of mental disorder.
Interaction between Food and Olsavas
Olsavas may take longer to act if you eat some foods while taking it. Follow your doctor's advice on this.
Interaction between Alcohol and Olsavas
Taking alcohol with Olsavas can be dangerous.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Benicar (olmesartan medoxomil)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 507
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 169-173